For patients who have been prescribed Idelvion
Idelvion is for the treatment of haemophilia B for both adults and children.1
Idelvion contains clotting factor nine (the factor that is missing from or reduced in your blood).1-4 This protein will help your blood to clot and can therefore prevent and treat bleeding in haemophilia B.1
Idelvion is injectable, the medicine can therefore be administered directly into your bloodstream. Your haemophilia care team will show you how.
People with haemophilia B have traditionally injected their medicine two or three times each week. But compared to these conventional therapies, Idelvion stays in your body for longer, so you may not need to use it as often.2,3
Idelvion is an extended half-life (EHL) product. These products use new technology that makes them stay and act in your body for longer than traditional treatments for haemophilia B, which may mean less frequent injections.4,5
- There are a number of factors, including age and level of physical activity, among others, that will determine the number of days between injections
- Your haemophilia care team will discuss with you the treatment dose and frequency that is right for you
If you have any questions about your Idelvion treatment – always ask advice from your haemophilia care team.
- Idelvion does not need to be stored in a refrigerator. Idelvion can be stored at room temperature (2-25°C). Do not store above 25 °C. Do not freeze. Keep vials in the outer carton in order to protect from light
- Idelvion (not reconstituted) can be stored for up to 3 years
- After reconstitution the product should be used immediately
Reporting of side effects
If you are concerned about any reactions or possible side effects it is important to contact your doctor, pharmacist or nurse immediately.
This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.